FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

Pfizer Relpax Recall

RELPAX (eletriptan HBr) tablets, 40 mg, packaged in a) 6-count (1 card x 6 tablets) per…

Pfizer Inc. · New York, NY

Risk level
Class II
Reported by FDA
Sep 4, 2019
Recall ID
D-1845-2019
Check your lot numberHow we source this data

Summary

Pfizer recalled Relpax starting Aug 14, 2019. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-1845-2019 on Sep 4, 2019. Reason: Microbial Contamination of Non-Sterile Products: contamination with Burkholderia and Pseudomonas. Status: Terminated.

Why it was recalled

Microbial Contamination of Non-Sterile Products: contamination with Burkholderia and Pseudomonas.

Product description

RELPAX (eletriptan HBr) tablets, 40 mg, packaged in a) 6-count (1 card x 6 tablets) per carton, NDC 0049-2340-45; b) 12-count (2 cards x 6 tablets) per carton, NDC 0049-2340-05, Rx only, Made in Ireland, Distributed by Pfizer Roerig, Division of Pfizer Inc., NY, NY 10017.

Lot numbers, UPCs & expiration codes

Lot #: a) AR5407, Exp 2022 FEB; b) CD4565, Exp 2022 FEB

Where it was sold

Nationwide in the USA and Puerto Rico.

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-1845-2019
Classification
Class II
Status
Terminated
Recall initiated
Aug 14, 2019
FDA report date
Sep 4, 2019
Quantity
a) 20,117 cartons; b) 2,502 cartons
Recall type
Voluntary: Firm initiated
Recalling firm
Pfizer Inc.

Original FDA data

Every field from FDA enforcement report D-1845-2019, exactly as published.

Show all FDA fields
City
New York
State
NY
Status
Terminated
Country
United States
Event ID
83533
Address
235 E 42nd St
Code information
Lot #: a) AR5407, Exp 2022 FEB; b) CD4565, Exp 2022 FEB
Postal code
10017-5703
Report date
Sep 4, 2019
Product type
Drugs
Recall number
D-1845-2019
Classification
Class II
Recalling firm
Pfizer Inc.
Product quantity
a) 20,117 cartons; b) 2,502 cartons
Termination date
Jun 20, 2023
Reason for recall
Microbial Contamination of Non-Sterile Products: contamination with Burkholderia and Pseudomonas.
Voluntary / mandated
Voluntary: Firm initiated
Product description
RELPAX (eletriptan HBr) tablets, 40 mg, packaged in a) 6-count (1 card x 6 tablets) per carton, NDC 0049-2340-45; b) 12-count (2 cards x 6 tablets) per carton, NDC 0049-2340-05, Rx only, Made in Ireland, Distributed by Pfizer Roerig, Division of Pfizer Inc., NY, NY 10017.
Distribution pattern
Nationwide in the USA and Puerto Rico.
Recall initiation date
Aug 14, 2019
Initial firm notification
Press Release
Center classification date
Aug 28, 2019

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-1845-2019, published Sep 4, 2019. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls